Description
BiSeptol Urinar for Men with Methylene Blue, 30 capsules, Dacia Plant
The concentrated formula, with results from the first use, designed to reduce the risk of bacterial contamination of the urinary tract, contains methylene blue and concentrated extracts of cranberry and juniper fruit.
- Urinary antiseptic
- Anti-inflammatory
- Diuretic
- Immunostimulant
- Helps maintain urinary tract health
- Prophylaxis and treatment of acute or recurrent urinary tract infections.
Ingredients:
Lingonberry (Vaccinium vitis-idaea) - fruit extract (300 mg); blueberry (Vaccinium myrtillus) - fruit extract (150 mg); juniper (Juniperus communis) - fruit extract 5:1 (100 mg); echinacea (Echinacea purpurea) - 5:1 extract with 4% polyphenols from stems and roots (50 mg); Methylene blue powder (5 mg); juniper (Juniperus communis) essential oil (1 mg); tea tree (Melaleuca alternifolia) essential oil (1 mg); oregano (Origanum vulgare) essential oil (1 mg); bulking agent: microcrystalline cellulose; anti-caking agents: colloidal silicon dioxide, magnesium salts of vegetable fatty acids.
How to use:
- 2-3 tablets daily, 30 minutes before meals
- Swallow the tablets with water
- If swallowing is difficult, the tablets can be split in two.
Contraindications:
Intolerance to any of the product's ingredients.
Presentations: 30 tablets
Features
| Product code | 414415 |
| Category | Urinary System, Vitamins & Supplements, Useful kits, Focused Ads (IT) |
| Product line | BiSeptol |
| Brand | Dacia Plant |
| Range | For Men |
| Quantity | 30 |
| Product type | Capsules |
BiSeptol Urinar for Men with Methylene Blue, 30 capsules, Dacia Plant
-
Autoship & Save
- Enjoy 5% discount on your order
- Repeat deliveries can save you up to € 6,60 / year
- Skip, change or cancel anytime¹
BiSeptol Urinar for Men with Methylene Blue, 30 capsules, Dacia Plant€ 11 € 10,45Save € 0,55 with Autoship & SaveQuantity: -
Pay securely with your preferred payment method
Reviews
All reviews
All reviews
Good product. Very helpful .
Delivered on time. Hope to see results soon.
Read original